Fire: Marked this version for translation

2024-02-20T12:00:04Z

Marked this version for translation

← Older revision		Revision as of 21:00, 20 February 2024
Line 1:		Line 1:
	<languages />		<languages />
	<translate>		<translate>
			<!--T:1-->
	{{Pathnav\|Medication\|Diabetes medication\|SGLT2 inhibitor\|frame=1}}		{{Pathnav\|Medication\|Diabetes medication\|SGLT2 inhibitor\|frame=1}}
	{{Short description\|Chemical compound}}		{{Short description\|Chemical compound}}
Line 12:		Line 13:
	\| caption = [[Haworth projection]] (bottom)		\| caption = [[Haworth projection]] (bottom)

			<!--T:2-->
	<!-- Clinical data -->		<!-- Clinical data -->
	\| tradename = Suglat		\| tradename = Suglat
Line 30:		Line 32:
	\| routes_of_administration = [[Oral administration\|By mouth]] ([[Tablet (pharmacy)\|tablets]])		\| routes_of_administration = [[Oral administration\|By mouth]] ([[Tablet (pharmacy)\|tablets]])

			<!--T:3-->
	<!-- Pharmacokinetic data -->		<!-- Pharmacokinetic data -->
	\| bioavailability = 90.2%		\| bioavailability = 90.2%
Line 40:		Line 43:
	\| excretion = [[Urine]] (67.9%), [[feces]] (32.7%)		\| excretion = [[Urine]] (67.9%), [[feces]] (32.7%)

			<!--T:4-->
	<!-- Identifiers -->		<!-- Identifiers -->
	\| CAS_number = 761423-87-4		\| CAS_number = 761423-87-4
Line 53:		Line 57:
	\| synonyms = (1''S'')-1,5-anhydro-1-''C''-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-<small>D</small>-glucitol		\| synonyms = (1''S'')-1,5-anhydro-1-''C''-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-<small>D</small>-glucitol

			<!--T:5-->
	<!-- Chemical data -->		<!-- Chemical data -->
	\| chemical_formula =		\| chemical_formula =
Line 61:		Line 66:
	}}		}}

			<!--T:6-->
	'''Ipragliflozin''' ([[International nonproprietary name\|INN]], trade names '''Suglat''') is a pharmaceutical drug for treatment of [[Diabetes mellitus type 2\|type 2 diabetes]]. Ipragliflozin, jointly developed by [[Astellas Pharma]] and Kotobuki Pharmaceutical, was approved in [[Japan]] on January 17, 2014, and in [[Russia]] on May 22, 2019.		'''Ipragliflozin''' ([[International nonproprietary name\|INN]], trade names '''Suglat''') is a pharmaceutical drug for treatment of [[Diabetes mellitus type 2\|type 2 diabetes]]. Ipragliflozin, jointly developed by [[Astellas Pharma]] and Kotobuki Pharmaceutical, was approved in [[Japan]] on January 17, 2014, and in [[Russia]] on May 22, 2019.

			<!--T:7-->
	Ipragliflozin is a [[SGLT2\|Sodium/glucose cotransporter 2 (SGLT2)]] inhibitor ([[gliflozin]]). These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Ipragliflozin reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2.		Ipragliflozin is a [[SGLT2\|Sodium/glucose cotransporter 2 (SGLT2)]] inhibitor ([[gliflozin]]). These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Ipragliflozin reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2.

	==Clinical trials==		==Clinical trials== <!--T:8-->
	The efficacy and safety of ipragliflozin were both observed in a [[Phases of clinical research#Phase III\|Phase III]] study in monotherapy and clinical studies used in combination with other hypoglycemic agents (6 types) in Japan.		The efficacy and safety of ipragliflozin were both observed in a [[Phases of clinical research#Phase III\|Phase III]] study in monotherapy and clinical studies used in combination with other hypoglycemic agents (6 types) in Japan.

			<!--T:9-->
	One placebo-controlled, double-blind study was carried out at 18 different sites in Korea and 12 in Taiwan. Patients were above 20 and had type 2 diabetes for atlas 12 weeks. They were given an 8-week period to clear their systems of all other drugs (besides metformin). Patients received either 50 mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibited from using any other anti diabetic drugs, other than metformin. The study ran for 24 weeks along with a 4-week follow-up period.		One placebo-controlled, double-blind study was carried out at 18 different sites in Korea and 12 in Taiwan. Patients were above 20 and had type 2 diabetes for atlas 12 weeks. They were given an 8-week period to clear their systems of all other drugs (besides metformin). Patients received either 50 mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibited from using any other anti diabetic drugs, other than metformin. The study ran for 24 weeks along with a 4-week follow-up period.
	The standard deviation in [[Glycated hemoglobin\|hemoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value\|''p'']] <0.001). The changes in fasting plasma glucose and bodyweight were also significantly greater in the ipragliflozin group, with between-group differences of −14.1 mg/dL and −1.24 kg, respectively (both ''p'' <0.001). The most common adverse events that appeared were [[Upper respiratory tract infection\|upper respiratory infection]]s and [[urinary tract infection]]s. From this it was concluded that ipragliflozin is both efficacious as well as safe.		The standard deviation in [[Glycated hemoglobin\|hemoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value\|''p'']] <0.001). The changes in fasting plasma glucose and bodyweight were also significantly greater in the ipragliflozin group, with between-group differences of −14.1 mg/dL and −1.24 kg, respectively (both ''p'' <0.001). The most common adverse events that appeared were [[Upper respiratory tract infection\|upper respiratory infection]]s and [[urinary tract infection]]s. From this it was concluded that ipragliflozin is both efficacious as well as safe.

			<!--T:10-->
	However, ipragliflozin is currently in Observational Case Control clinical trial to see the long-term (over three years) safety of using ipragliflozin. The estimated completion of this trial is October 2018.		However, ipragliflozin is currently in Observational Case Control clinical trial to see the long-term (over three years) safety of using ipragliflozin. The estimated completion of this trial is October 2018.
	* 18 October 2016: Astellas completes a clinical trial for Type-2 diabetes mellitus in Japan prior to October 2016		* 18 October 2016: Astellas completes a clinical trial for Type-2 diabetes mellitus in Japan prior to October 2016
Line 76:		Line 85:
	* 1 August 2016: Phase III clinical trials in type 1 diabetes mellitus (combination therapy) in Japan		* 1 August 2016: Phase III clinical trials in type 1 diabetes mellitus (combination therapy) in Japan

			<!--T:11-->
	Ipragliflozin was also in development for type 2 diabetes mellitus in the U.S., Europe and other countries, and three phase II trials were completed in combination with metformin. This was since discontinued.		Ipragliflozin was also in development for type 2 diabetes mellitus in the U.S., Europe and other countries, and three phase II trials were completed in combination with metformin. This was since discontinued.

	==Commercialization==		==Commercialization== <!--T:12-->
	As of 2014, Suglat was the top reimbursed drug in Japan. Peak sales reached {{USD}}515 million with 800,000 and the cost per patient reached {{USD}}644 per year.		As of 2014, Suglat was the top reimbursed drug in Japan. Peak sales reached {{USD}}515 million with 800,000 and the cost per patient reached {{USD}}644 per year.
	In 2014, the market for selective SGLT2 inhibitors in Japan was around 9 billion yen. Suglat's share of this market was around 49%.		In 2014, the market for selective SGLT2 inhibitors in Japan was around 9 billion yen. Suglat's share of this market was around 49%.

			<!--T:13-->
	In 2015, sales of Suglat grew 77.8% to 7.3 billion [[Japanese yen\|yen]], following the availability of long-term prescriptions from May 2015. Suglat's share of the market for selective SGLT2 inhibitors in Japan was around 39%.		In 2015, sales of Suglat grew 77.8% to 7.3 billion [[Japanese yen\|yen]], following the availability of long-term prescriptions from May 2015. Suglat's share of the market for selective SGLT2 inhibitors in Japan was around 39%.

			<!--T:14-->
	The projected sales in 2016 is to jump all the way to 12.5 billion yen.		The projected sales in 2016 is to jump all the way to 12.5 billion yen.

	==Marketing==		==Marketing== <!--T:15-->
	Ipragliflozin was the first drug of its kind sold by any company in Japan. Therefore, Astellas will focus their marketing in order to maintain the top share of this market that it holds. Astellas has been building up post-marketing data in regard to the efficacy and safety of ipragliflozin. By supplying information based on this data, Astellas aims to increase the market penetration of ipragliflozin in the Japanese market.		Ipragliflozin was the first drug of its kind sold by any company in Japan. Therefore, Astellas will focus their marketing in order to maintain the top share of this market that it holds. Astellas has been building up post-marketing data in regard to the efficacy and safety of ipragliflozin. By supplying information based on this data, Astellas aims to increase the market penetration of ipragliflozin in the Japanese market.

			<!--T:16-->
	In 2015, Astellas additionally launched Suglat in the Republic of Korea and [[Febuxostat\|Feburic]] in Thailand.		In 2015, Astellas additionally launched Suglat in the Republic of Korea and [[Febuxostat\|Feburic]] in Thailand.

	==Intellectual Property==		==Intellectual Property== <!--T:17-->
	In May 2013, Boehringer Ingelheim of Germany applied for a Methods of Treatment, Pharmaceutical Compositions and uses thereof patent. This patent application included SGLT2 inhibitor ipragliflozin.		In May 2013, Boehringer Ingelheim of Germany applied for a Methods of Treatment, Pharmaceutical Compositions and uses thereof patent. This patent application included SGLT2 inhibitor ipragliflozin.
	In April 2014, Boehringer Ingelheim applied for usage of SGLT2 inhibitors in equine animals. The usage of these inhibitors in an animal study allows for progression in the application in humans for more than just diabetes.		In April 2014, Boehringer Ingelheim applied for usage of SGLT2 inhibitors in equine animals. The usage of these inhibitors in an animal study allows for progression in the application in humans for more than just diabetes.
Line 99:		Line 112:


			<!--T:18-->
	{{Oral hypoglycemics}}		{{Oral hypoglycemics}}
	{{Sodium-glucose transporter modulators}}		{{Sodium-glucose transporter modulators}}

			<!--T:19-->
	{{二次利用\|date=10 October 2023}}		{{二次利用\|date=10 October 2023}}
	[[Category:Benzothiophenes]]		[[Category:Benzothiophenes]]

Fire at 11:59, 20 February 2024

2024-02-20T11:59:47Z

← Older revision		Revision as of 20:59, 20 February 2024
Line 1:		Line 1:
			<languages />
			<translate>
	{{Pathnav\|Medication\|Diabetes medication\|SGLT2 inhibitor\|frame=1}}		{{Pathnav\|Medication\|Diabetes medication\|SGLT2 inhibitor\|frame=1}}
	{{Short description\|Chemical compound}}		{{Short description\|Chemical compound}}
Line 105:		Line 107:
	[[Category:SGLT2 inhibitors]]		[[Category:SGLT2 inhibitors]]
	[[Category:Fluoroarenes]]		[[Category:Fluoroarenes]]
			</translate>

Fire at 10:20, 18 February 2024

2024-02-18T10:20:33Z

← Older revision		Revision as of 19:20, 18 February 2024
Line 1:		Line 1:
			{{Pathnav\|Medication\|Diabetes medication\|SGLT2 inhibitor\|frame=1}}
	{{Short description\|Chemical compound}}		{{Short description\|Chemical compound}}
	{{Infobox drug		{{Infobox drug

Fire: Created page with "{{Short description|Chemical compound}} {{Infobox drug | drug_name = | IUPAC_name = (1''S'')-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol | image = Ipragliflozin structure.svg | width = 275 | image2 = Haworth projection of ipragliflozin.svg | width2 = 225 | caption = Haworth projection (bottom) | tradename = Suglat | Drugs.com = | MedlinePlus = | pregnancy_AU =

Ipragliflozin - Revision history

Fire: Marked this version for translation

Fire at 11:59, 20 February 2024

Fire at 10:20, 18 February 2024